[go: up one dir, main page]

GB202107709D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB202107709D0
GB202107709D0 GBGB2107709.4A GB202107709A GB202107709D0 GB 202107709 D0 GB202107709 D0 GB 202107709D0 GB 202107709 A GB202107709 A GB 202107709A GB 202107709 D0 GB202107709 D0 GB 202107709D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2107709.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, MedImmune Ltd filed Critical ADC Therapeutics SA
Priority to GBGB2107709.4A priority Critical patent/GB202107709D0/en
Publication of GB202107709D0 publication Critical patent/GB202107709D0/en
Priority to PCT/EP2022/063158 priority patent/WO2022248268A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
GBGB2107709.4A 2021-05-28 2021-05-28 Combination therapy Ceased GB202107709D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2107709.4A GB202107709D0 (en) 2021-05-28 2021-05-28 Combination therapy
PCT/EP2022/063158 WO2022248268A1 (en) 2021-05-28 2022-05-16 Combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2107709.4A GB202107709D0 (en) 2021-05-28 2021-05-28 Combination therapy

Publications (1)

Publication Number Publication Date
GB202107709D0 true GB202107709D0 (en) 2021-07-14

Family

ID=76741176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2107709.4A Ceased GB202107709D0 (en) 2021-05-28 2021-05-28 Combination therapy

Country Status (1)

Country Link
GB (1) GB202107709D0 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. AAD00698
"Uniprot", Database accession no. P16410
ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
BROWN, J. A., J IMMUNOL., vol. 70, 2003, pages 1257 - 1266
CARTER, P., NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 343 - 357
CAS , no. 391210-10-9
CAS, no. 41575-94-4
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DONG H. ET AL., NAT. MED., vol. 8, 2002, pages 793 - 800
HAMANN P, EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1087 - 1103
JANEWAY, C.TRAVERS, P.WALPORT, M.SHLOMCHIK: "Immuno Biology", 2001, GARLAND PUBLISHING
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
LAMBERT J, CURRENT OPIN. IN PHARMACOL., vol. 5, 2005, pages 543 - 549
LIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, no. 30I, 2008, pages I-6
LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
NOMI, T. ET AL., CLIN. CANCER RES., vol. 13, 2007, pages 2151 - 2157
OKAZAKIHONJO, INT. IMMUNOL., vol. 19, 2007, pages 813 - 824
PAYNE, G, CANCER CELL, vol. 3, 2003, pages 207 - 212
RAJU K ET AL.: "Review of Indications of FDA-Approved Immune Checkpoint modulators per NCCN Guidelines with the Level of Evidence.", CANCERS, vol. 12, no. 3, 20 March 2020 (2020-03-20), pages 738
STROME, S. E. ET AL., CANCER RES., vol. 63, 2003, pages 6501 - 6505
SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614
THOMPSON, R.H. ET AL., CANCER RES., vol. 66, no. 4, 2006, pages 3381 - 2337
TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337
TSUSHIMA, F. ET AL., ORAL ONEAL, vol. 42, 2006, pages 268 - 274
WU ET AL., NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1137 - 1145
XIE ET AL., EXPERT. OPIN. BIOL. THER., vol. 6, no. 3, 2006, pages 281 - 291
ZHANG, X. ET AL., IMMUNITY, vol. 20, 2004, pages 337 - 347

Similar Documents

Publication Publication Date Title
IL304223A (en) Combination therapy
IL319599A (en) Combination therapy
GB202103164D0 (en) Therapy
GB202004189D0 (en) Combination therapy
GB202002639D0 (en) Therapy
IL318268A (en) Combination therapy
GB202111288D0 (en) Combination therapy
GB202104037D0 (en) Combination therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
GB202109377D0 (en) Combination therapy
GB202109373D0 (en) Combination therapy
GB202109375D0 (en) Combination therapy
GB202107824D0 (en) Combination therapy
GB202107709D0 (en) Combination therapy
GB202107706D0 (en) Combination therapy
GB202107713D0 (en) Combination therapy
GB202015916D0 (en) Combination therapy
GB202012161D0 (en) Combination therapy
GB202009178D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)